Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

2019109 citationsJournal Articlebronze Open Access

Authors

Helen Stacey · Diablo Clinical Research

Jeffrey B. Rosen · Clinical Research of South Florida

James T. Peterson · Foothill Family Clinic

Angela Williams‐Diaz · Merck & Co., Inc., Rahway, NJ, USA (United States)

Vanita Gakhar · Merck & Co., Inc., Rahway, NJ, USA (United States)

Tina M. Sterling · Merck & Co., Inc., Rahway, NJ, USA (United States)

Camilo J. Acosta

Abstract

In healthy adults ≥ 50 years of age, both new formulations of PCV15 displayed acceptable safety profiles and induced serotype-specific immune responses comparable to PCV13.

Topics & Keywords

Pneumonia and Respiratory Infections Respiratory viral infections research Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Human Vaccines & Immunotherapeutics

Volume 15, Issue 3, pp. 530-539

DOI: 10.1080/21645515.2018.1532249

Field-Weighted Citation Impact: 10.06